 |
PDBsum entry 1k3a
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.1
- receptor protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
Bound ligand (Het Group name = )
matches with 81.25% similarity
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Nat Struct Biol
8:1058-1063
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.
|
|
S.Favelyukis,
J.H.Till,
S.R.Hubbard,
W.T.Miller.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The insulin-like growth factor 1 (IGF1) receptor is closely related to the
insulin receptor. However, the unique biological functions of IGF1 receptor make
it a target for therapeutic intervention in human cancer. Using its isolated
tyrosine kinase domain, we show that the IGF1 receptor is regulated by
intermolecular autophosphorylation at three sites within the kinase activation
loop. Steady-state kinetic analyses of the isolated phosphorylated forms of the
IGF1 receptor kinase (IGF1RK) reveal that each autophosphorylation event
increases enzyme turnover number and decreases Km for ATP and peptide. We have
determined the 2.1 A-resolution crystal structure of the tris-phosphorylated
form of IGF1RK in complex with an ATP analog and a specific peptide substrate.
The structure of IGF1RK reveals how the enzyme recognizes peptides containing
hydrophobic residues at the P+1 and P+3 positions and how autophosphorylation
stabilizes the activation loop in a conformation that facilitates catalysis.
Although the nucleotide binding cleft is conserved between IGF1RK and the
insulin receptor kinase, sequence differences in the nearby interlobe linker
could potentially be exploited for anticancer drug design.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. Overall structure of IGF1RK and activation loop
interactions. a, Ribbon diagram of the IGF1RK structure. -strands
(numbered) are shown in cyan; -helices
(lettered), in red. The peptide is colored orange with the
phosphate-acceptor Tyr shown in ball-and-stick representation.
The nucleotide analog, AMP-PCP, is also shown in ball-and-stick
representation (black). The dashed gray coil represents the
disordered portion of the kinase insert. The N-terminal (NT) end
of the structure is labeled. The C-terminal end is after J,
hidden behind 8.
b, Interactions within the A-loop (in stereo). The A-loop
(residues 1,123 -1,145) is shown as a backbone worm (green) with
side chains of selected residues shown in stick representation
(carbon = green, nitrogen = blue, oxygen = red, sulfur = yellow
and phosphorus = black). Residues contributing to stabilization
of the activation loop via hydrophobic interactions are shown
with a molecular surface. Hydrogen bonds are shown as dashed
lines (black). c, Interactions between the A-loop and other
kinase segments (in stereo). A backbone worm representation is
shown for the A-loop (green), a segment including part of the
catalytic loop (residues 1,100 -1,105 in orange) and a segment
corresponding to 12
(residues 1,157 -1,159 in gray). Side chain and main chain atoms
are shown in stick representation with the same color scheme as
in (b) with the exception of carbon, which is colored the same
as the corresponding backbone worm. For clarity, pTyr 1136 has
been omitted.
|
 |
Figure 3.
Figure 3. IGF1RK peptide substrate binding and comparison to
IRK. a, Stereo view of the 2F[o] - F[c] electron density map
(2.1 Ć resolution, 1 contour)
for the peptide substrate. The electron density is shown as a
wire mesh (blue); the peptide substrate (orange), in stick
representation. b, Stereo view of interactions at the IGF1RK
-peptide substrate interface. A semitransparent molecular
surface (gray) of IGF1RK is shown with residues (labeled and
displayed in stick representation) that define the peptide
binding cleft and interact with the peptide substrate. The
peptide (shown in stick representation) is illustrated without a
molecular surface, with residues labeled relative to the
phosphate acceptor Tyr (P0). Hydrogen bonds between the peptide
and the enzyme are shown as black lines. Bond coloring is carbon
= orange, oxygen = red, nitrogen = blue, sulfur = green and
phosphorus = yellow. c, A molecular surface representation of
IGF1RK illustrating surface residue differences between IGF1RK
and IRK. The molecular surface contributed by differing side
chains between the two structures are colored green. The
molecular surface contributed by the Thr 1053 side chain in the
interlobe linker is colored yellow (see text). d, A backbone
worm representation of IGF1RK. Segments corresponding to
residues that differ between IGF1RK and IRK are colored green.
In (c,d), stick representations of the nucleotide analog
(AMP-PCP) and peptide are shown. The semitransparent segment
represents the portion of the kinase insert disordered in the
structure. Bond coloring is the same as in (a).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Struct Biol
(2001,
8,
1058-1063)
copyright 2001.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
D.Lesuisse,
J.Mauger,
C.Nemecek,
S.Maignan,
J.Boiziau,
G.Harlow,
A.Hittinger,
S.Ruf,
H.Strobel,
A.Nair,
K.Ritter,
J.L.Malleron,
A.Dagallier,
Y.El-Ahmad,
J.P.Guilloteau,
H.Guizani,
H.Bouchard,
and
C.Venot
(2011).
Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.
|
| |
Bioorg Med Chem Lett,
21,
2224-2228.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.Buck,
and
M.Mulvihill
(2011).
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
|
| |
Expert Opin Investig Drugs,
20,
605-621.
|
 |
|
|
|
|
 |
L.Croci,
V.Barili,
D.Chia,
L.Massimino,
R.van Vugt,
G.Masserdotti,
R.Longhi,
P.Rotwein,
and
G.G.Consalez
(2011).
Local insulin-like growth factor I expression is essential for Purkinje neuron survival at birth.
|
| |
Cell Death Differ,
18,
48-59.
|
 |
|
|
|
|
 |
C.C.Lee,
Y.Jia,
N.Li,
X.Sun,
K.Ng,
E.Ambing,
M.Y.Gao,
S.Hua,
C.Chen,
S.Kim,
P.Y.Michellys,
S.A.Lesley,
J.L.Harris,
and
G.Spraggon
(2010).
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
|
| |
Biochem J,
430,
425-437.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.Erdmann,
C.Zimmermann,
P.Fontana,
J.C.Hau,
A.De Pover,
and
P.Chène
(2010).
Simultaneous protein expression and modification: an efficient approach for production of unphosphorylated and biotinylated receptor tyrosine kinases by triple infection in the baculovirus expression system.
|
| |
J Biomol Tech,
21,
9.
|
 |
|
|
|
|
 |
K.Yavari,
M.Taghikhani,
M.Ghannadi Maragheh,
S.A.Mesbah-Namin,
and
M.H.Babaei
(2010).
Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells.
|
| |
Int J Colorectal Dis,
25,
9.
|
 |
|
|
|
|
 |
M.D.Mavalli,
D.J.DiGirolamo,
Y.Fan,
R.C.Riddle,
K.S.Campbell,
T.van Groen,
S.J.Frank,
M.A.Sperling,
K.A.Esser,
M.M.Bamman,
and
T.L.Clemens
(2010).
Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice.
|
| |
J Clin Invest,
120,
4007-4020.
|
 |
|
|
|
|
 |
V.N.Uversky
(2010).
Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept.
|
| |
Expert Rev Proteomics,
7,
543-564.
|
 |
|
|
|
|
 |
B.Zhou,
and
C.F.Wong
(2009).
A computational study of the phosphorylation mechanism of the insulin receptor tyrosine kinase.
|
| |
J Phys Chem A,
113,
5144-5150.
|
 |
|
|
|
|
 |
E.D.Lew,
C.M.Furdui,
K.S.Anderson,
and
J.Schlessinger
(2009).
The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations.
|
| |
Sci Signal,
2,
ra6.
|
 |
|
|
|
|
 |
E.Gualco,
J.Y.Wang,
L.Del Valle,
K.Urbanska,
F.Peruzzi,
K.Khalili,
S.Amini,
and
K.Reiss
(2009).
IGF-IR in neuroprotection and brain tumors.
|
| |
Front Biosci,
14,
352-375.
|
 |
|
|
|
|
 |
J.H.Bae,
E.D.Lew,
S.Yuzawa,
F.Tomé,
I.Lax,
and
J.Schlessinger
(2009).
The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site.
|
| |
Cell,
138,
514-524.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Goetsch,
and
N.Corvaïa
(2009).
Insulin-like growth factor receptor type I as a target for cancer therapy.
|
| |
Immunotherapy,
1,
265-279.
|
 |
|
|
|
|
 |
M.Yin,
X.Guan,
Z.Liao,
and
Q.Wei
(2009).
Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review.
|
| |
Am J Transl Res,
1,
101-114.
|
 |
|
|
|
|
 |
R.Li,
A.Pourpak,
and
S.W.Morris
(2009).
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.
|
| |
J Med Chem,
52,
4981-5004.
|
 |
|
|
|
|
 |
R.Thomas,
and
M.H.Kim
(2009).
A HIF-1alpha-dependent autocrine feedback loop promotes survival of serum-deprived prostate cancer cells.
|
| |
Prostate,
69,
263-275.
|
 |
|
|
|
|
 |
W.N.Pappano,
P.M.Jung,
J.A.Meulbroek,
Y.C.Wang,
R.D.Hubbard,
Q.Zhang,
M.M.Grudzien,
N.B.Soni,
E.F.Johnson,
G.S.Sheppard,
C.Donawho,
F.G.Buchanan,
S.K.Davidsen,
R.L.Bell,
and
J.Wang
(2009).
Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.
|
| |
BMC Cancer,
9,
314.
|
 |
|
|
|
|
 |
Z.Huang,
and
C.F.Wong
(2009).
Docking flexible peptide to flexible protein by molecular dynamics using two implicit-solvent models: an evaluation in protein kinase and phosphatase systems.
|
| |
J Phys Chem B,
113,
14343-14354.
|
 |
|
|
|
|
 |
B.E.Turk
(2008).
Understanding and exploiting substrate recognition by protein kinases.
|
| |
Curr Opin Chem Biol,
12,
4.
|
 |
|
|
|
|
 |
D.C.Lee,
J.Zheng,
Y.M.She,
and
Z.Jia
(2008).
Structure of Escherichia coli tyrosine kinase Etk reveals a novel activation mechanism.
|
| |
EMBO J,
27,
1758-1766.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.D.Bikle
(2008).
Integrins, insulin like growth factors, and the skeletal response to load.
|
| |
Osteoporos Int,
19,
1237-1246.
|
 |
|
|
|
|
 |
E.Ozkirimli,
S.S.Yadav,
W.T.Miller,
and
C.B.Post
(2008).
An electrostatic network and long-range regulation of Src kinases.
|
| |
Protein Sci,
17,
1871-1880.
|
 |
|
|
|
|
 |
H.Chen,
C.F.Xu,
J.Ma,
A.V.Eliseenkova,
W.Li,
P.M.Pollock,
N.Pitteloud,
W.T.Miller,
T.A.Neubert,
and
M.Mohammadi
(2008).
A crystallographic snapshot of tyrosine trans-phosphorylation in action.
|
| |
Proc Natl Acad Sci U S A,
105,
19660-19665.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Eswaran,
A.Bernad,
J.M.Ligos,
B.Guinea,
J.E.Debreczeni,
F.Sobott,
S.A.Parker,
R.Najmanovich,
B.E.Turk,
and
S.Knapp
(2008).
Structure of the human protein kinase MPSK1 reveals an atypical activation loop architecture.
|
| |
Structure,
16,
115-124.
|
 |
|
|
|
|
 |
J.Wu,
W.Li,
B.P.Craddock,
K.W.Foreman,
M.J.Mulvihill,
Q.S.Ji,
W.T.Miller,
and
S.R.Hubbard
(2008).
Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor.
|
| |
EMBO J,
27,
1985-1994.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Wu,
Y.D.Tseng,
C.F.Xu,
T.A.Neubert,
M.F.White,
and
S.R.Hubbard
(2008).
Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2.
|
| |
Nat Struct Mol Biol,
15,
251-258.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Kundrapu,
L.Colenberg,
and
R.J.Duhé
(2008).
Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation.
|
| |
Cell Biochem Biophys,
52,
103-112.
|
 |
|
|
|
|
 |
B.P.Craddock,
C.Cotter,
and
W.T.Miller
(2007).
Autoinhibition of the insulin-like growth factor I receptor by the juxtamembrane region.
|
| |
FEBS Lett,
581,
3235-3240.
|
 |
|
|
|
|
 |
B.Sehat,
S.Andersson,
R.Vasilcanu,
L.Girnita,
and
O.Larsson
(2007).
Role of ubiquitination in IGF-1 receptor signaling and degradation.
|
| |
PLoS ONE,
2,
e340.
|
 |
|
|
|
|
 |
E.D.Lew,
J.H.Bae,
E.Rohmann,
B.Wollnik,
and
J.Schlessinger
(2007).
Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation.
|
| |
Proc Natl Acad Sci U S A,
104,
19802-19807.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.Chen,
J.Ma,
W.Li,
A.V.Eliseenkova,
C.Xu,
T.A.Neubert,
W.T.Miller,
and
M.Mohammadi
(2007).
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.
|
| |
Mol Cell,
27,
717-730.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.D.Hubbard,
and
J.L.Wilsbacher
(2007).
Advances towards the Development of ATP-Competitive Small-Molecule Inhibitors of the Insulin-Like Growth Factor Receptor (IGF-IR).
|
| |
ChemMedChem,
2,
41-46.
|
 |
|
|
|
|
 |
Y.Tao,
V.Pinzi,
J.Bourhis,
and
E.Deutsch
(2007).
Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.
|
| |
Nat Clin Pract Oncol,
4,
591-602.
|
 |
|
|
|
|
 |
A.M.Burza,
I.Pekala,
J.Sikora,
P.Siedlecki,
P.MaĆagocki,
M.Bucholc,
L.Koper,
P.Zielenkiewicz,
M.Dadlez,
and
G.Dobrowolska
(2006).
Nicotiana tabacum osmotic stress-activated kinase is regulated by phosphorylation on Ser-154 and Ser-158 in the kinase activation loop.
|
| |
J Biol Chem,
281,
34299-34311.
|
 |
|
|
|
|
 |
C.M.Furdui,
E.D.Lew,
J.Schlessinger,
and
K.S.Anderson
(2006).
Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction.
|
| |
Mol Cell,
21,
711-717.
|
 |
|
|
|
|
 |
D.Vasilcanu,
W.H.Weng,
A.Girnita,
W.O.Lui,
R.Vasilcanu,
M.Axelson,
O.Larsson,
C.Larsson,
and
L.Girnita
(2006).
The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection.
|
| |
Oncogene,
25,
3186-3195.
|
 |
|
|
|
|
 |
H.Remaut,
and
G.Waksman
(2006).
Protein-protein interaction through beta-strand addition.
|
| |
Trends Biochem Sci,
31,
436-444.
|
 |
|
|
|
|
 |
W.Li,
and
W.T.Miller
(2006).
Role of the activation loop tyrosines in regulation of the insulin-like growth factor I receptor-tyrosine kinase.
|
| |
J Biol Chem,
281,
23785-23791.
|
 |
|
|
|
|
 |
F.Hofmann,
and
C.García-Echeverría
(2005).
Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.
|
| |
Drug Discov Today,
10,
1041-1047.
|
 |
|
|
|
|
 |
N.Yokoyama,
J.Lougheed,
and
W.T.Miller
(2005).
Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual hydroxyamino acid specificity in a tyrosine kinase.
|
| |
J Biol Chem,
280,
42219-42226.
|
 |
|
|
|
|
 |
O.Larsson,
A.Girnita,
and
L.Girnita
(2005).
Role of insulin-like growth factor 1 receptor signalling in cancer.
|
| |
Br J Cancer,
92,
2097-2101.
|
 |
|
|
|
|
 |
R.S.Depetris,
J.Hu,
I.Gimpelevich,
L.J.Holt,
R.J.Daly,
and
S.R.Hubbard
(2005).
Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14.
|
| |
Mol Cell,
20,
325-333.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.J.Boggon,
Y.Li,
P.W.Manley,
and
M.J.Eck
(2005).
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.
|
| |
Blood,
106,
996.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.C.Lougheed,
R.H.Chen,
P.Mak,
and
T.J.Stout
(2004).
Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1.
|
| |
J Biol Chem,
279,
44039-44045.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Y.Niv,
H.Rubin,
J.Cohen,
L.Tsirulnikov,
T.Licht,
A.Peretzman-Shemer,
E.Cna'an,
A.Tartakovsky,
I.Stein,
S.Albeck,
I.Weinstein,
M.Goldenberg-Furmanov,
D.Tobi,
E.Cohen,
M.Laster,
S.A.Ben-Sasson,
and
H.Reuveni
(2004).
Sequence-based design of kinase inhibitors applicable for therapeutics and target identification.
|
| |
J Biol Chem,
279,
1242-1255.
|
 |
|
|
|
|
 |
R.D.Meyer,
A.J.Singh,
and
N.Rahimi
(2004).
The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signaling.
|
| |
J Biol Chem,
279,
735-742.
|
 |
|
|
|
|
 |
E.G.Stein,
R.Ghirlando,
and
S.R.Hubbard
(2003).
Structural basis for dimerization of the Grb10 Src homology 2 domain. Implications for ligand specificity.
|
| |
J Biol Chem,
278,
13257-13264.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Li,
N.D.Covino,
E.G.Stein,
J.H.Till,
and
S.R.Hubbard
(2003).
Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor.
|
| |
J Biol Chem,
278,
26007-26014.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.J.Giordano,
D.G.Thomas,
R.Kuick,
M.Lizyness,
D.E.Misek,
A.L.Smith,
D.Sanders,
R.T.Aljundi,
P.G.Gauger,
N.W.Thompson,
J.M.Taylor,
and
S.M.Hanash
(2003).
Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.
|
| |
Am J Pathol,
162,
521-531.
|
 |
|
|
|
|
 |
D.G.Gilliland,
and
J.D.Griffin
(2002).
Role of FLT3 in leukemia.
|
| |
Curr Opin Hematol,
9,
274-281.
|
 |
|
|
|
|
 |
H.Qiu,
and
W.T.Miller
(2002).
Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition.
|
| |
J Biol Chem,
277,
34634-34641.
|
 |
|
|
|
|
 |
J.H.Till,
M.Becerra,
A.Watty,
Y.Lu,
Y.Ma,
T.A.Neubert,
S.J.Burden,
and
S.R.Hubbard
(2002).
Crystal structure of the MuSK tyrosine kinase: insights into receptor autoregulation.
|
| |
Structure,
10,
1187-1196.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.F.Iversen,
K.B.Moller,
A.K.Pedersen,
G.H.Peters,
A.S.Petersen,
H.S.Andersen,
S.Branner,
S.B.Mortensen,
and
N.P.Moller
(2002).
Structure determination of T cell protein-tyrosine phosphatase.
|
| |
J Biol Chem,
277,
19982-19990.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Munshi,
M.Kornienko,
D.L.Hall,
J.C.Reid,
L.Waxman,
S.M.Stirdivant,
P.L.Darke,
and
L.C.Kuo
(2002).
Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity.
|
| |
J Biol Chem,
277,
38797-38802.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |